Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neena Brizmohun

Neena Brizmohun writes and commissions news, features and analysis to meet the regulatory, business and market access information needs of the companies and regulatory agencies that operate in the pharmaceutical and medical device space worldwide.

Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.

A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Set Alert for Articles By Neena Brizmohun

Latest From Neena Brizmohun

France Invites Advanced Therapy Makers To Use Fast-Track Trial Approval Pathway

Updated guidance on France’s experimental fast-track procedure for approving clinical trials shows that the pathway has entered a new phase.

France Clinical Trials

Australia Tries Again At Tightening Personalized And 3D-Printed Device Rules

The Therapeutics Goods Administration has begun a second public consultation on how it intends to improve its rules for 3D-printed and other personalized medical devices after stakeholders called for more clarification to proposals made in 2017.

Policy & Regulation Australia

Software: Australia Plans Reforms While Canada Consults On Guidance

Australia is proposing to introduce new medical device software rules that would result in a number of changes for industry. Health Canada, meanwhile, has developed a draft guidance for software as a medical device to better define the regulatory compliance requirements for emerging technologies.

Canada Australia

US Yes To Two More Countries Under EU Inspections Deal

The US drug regulator may now rely on a total of 22 EU member states whose inspection results can replace its own inspections.

Manufacturing North America

EMA Checklist To Help Companies Submit 'First Time Right' MAAs

A new checklist for companies from the European Medicines Agency is designed to facilitate the agency's validation of initial marketing authorization applications and make this process more predictable and easier to navigate.

Drug Review Regulation

EMA Portal To Speed Things Up For Parallel Distributors

The European Medicines Agency says that its IRIS portal will reduce the time needed for parallel distributors to prepare and submit notifications.

Distribution Europe
See All